NO333157B1 - Fosfolipidblaere, modifiserte antigen-presenterende celler, fremgangsmate for inkorporering av antigener inn i dendrittiske celler og farmasoytisk sammensetning. - Google Patents

Fosfolipidblaere, modifiserte antigen-presenterende celler, fremgangsmate for inkorporering av antigener inn i dendrittiske celler og farmasoytisk sammensetning. Download PDF

Info

Publication number: NO333157B1
Authority: NO; Norway
Prior art keywords: phospholipid; antigen; cells; presenting cells; vesicle
Prior art date: 2000-03-24

Application number

NO20024571A

Other languages

English (en)

Norwegian (no)

Other versions

NO20024571L (no

NO20024571D0 (no

Inventor

James Dobbit

Original Assignee

Lamellar Biomedical Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-24

Filing date

2002-09-24

Publication date

2013-03-18

2002-09-24 Application filed by Lamellar Biomedical Ltd filed Critical Lamellar Biomedical Ltd

2002-09-24 Publication of NO20024571D0 publication Critical patent/NO20024571D0/no

2002-10-14 Publication of NO20024571L publication Critical patent/NO20024571L/no

2013-03-18 Publication of NO333157B1 publication Critical patent/NO333157B1/no

Links

150000003904 phospholipids Chemical class 0.000 title claims abstract description 118
102000036639 antigens Human genes 0.000 title claims abstract description 66
108091007433 antigens Proteins 0.000 title claims abstract description 66
239000000427 antigen Substances 0.000 title claims abstract description 65
210000000612 antigen-presenting cell Anatomy 0.000 title claims abstract description 46
238000000034 method Methods 0.000 title claims abstract description 30
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 5
210000004443 dendritic cell Anatomy 0.000 title claims description 54
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 43
239000000203 mixture Substances 0.000 claims abstract description 26
239000002671 adjuvant Substances 0.000 claims abstract description 17
230000000694 effects Effects 0.000 claims abstract description 9
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 54
108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 claims description 31
235000012000 cholesterol Nutrition 0.000 claims description 27
108090000623 proteins and genes Proteins 0.000 claims description 21
102000004169 proteins and genes Human genes 0.000 claims description 19
230000028993 immune response Effects 0.000 claims description 12
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 10
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 9
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 9
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 9
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 9
239000003795 chemical substances by application Substances 0.000 claims description 9
150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 9
230000004044 response Effects 0.000 claims description 9
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 8
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 8
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 claims description 7
238000000338 in vitro Methods 0.000 claims description 7
230000001939 inductive effect Effects 0.000 claims description 5
150000003905 phosphatidylinositols Chemical class 0.000 claims description 4
230000024932 T cell mediated immunity Effects 0.000 claims description 3
230000001024 immunotherapeutic effect Effects 0.000 claims description 3
102000040430 polynucleotide Human genes 0.000 claims description 3
108091033319 polynucleotide Proteins 0.000 claims description 3
229960005486 vaccine Drugs 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 claims 2
210000004027 cell Anatomy 0.000 abstract description 43
102000004196 processed proteins & peptides Human genes 0.000 abstract description 18
210000000987 immune system Anatomy 0.000 abstract description 6
238000002360 preparation method Methods 0.000 abstract description 4
150000005829 chemical entities Chemical class 0.000 abstract 1
102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 description 29
239000002502 liposome Substances 0.000 description 28
210000001519 tissue Anatomy 0.000 description 26
102000002812 Heat-Shock Proteins Human genes 0.000 description 18
108010004889 Heat-Shock Proteins Proteins 0.000 description 18
210000004379 membrane Anatomy 0.000 description 16
239000012528 membrane Substances 0.000 description 16
230000000890 antigenic effect Effects 0.000 description 14
150000001413 amino acids Chemical group 0.000 description 12
210000004072 lung Anatomy 0.000 description 11
206010018691 Granuloma Diseases 0.000 description 10
206010028980 Neoplasm Diseases 0.000 description 10
238000004519 manufacturing process Methods 0.000 description 9
239000000463 material Substances 0.000 description 9
210000001744 T-lymphocyte Anatomy 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
241000894006 Bacteria Species 0.000 description 7
201000011510 cancer Diseases 0.000 description 7
230000006870 function Effects 0.000 description 7
244000005700 microbiome Species 0.000 description 7
230000008569 process Effects 0.000 description 7
239000000126 substance Substances 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
150000002632 lipids Chemical class 0.000 description 6
241000282412 Homo Species 0.000 description 5
238000009826 distribution Methods 0.000 description 5
230000003308 immunostimulating effect Effects 0.000 description 5
210000003712 lysosome Anatomy 0.000 description 5
230000001868 lysosomic effect Effects 0.000 description 5
210000002540 macrophage Anatomy 0.000 description 5
210000004303 peritoneum Anatomy 0.000 description 5
238000002255 vaccination Methods 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
230000004927 fusion Effects 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
210000004324 lymphatic system Anatomy 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
239000002609 medium Substances 0.000 description 4
210000000680 phagosome Anatomy 0.000 description 4
239000005871 repellent Substances 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
102000005431 Molecular Chaperones Human genes 0.000 description 3
108010006519 Molecular Chaperones Proteins 0.000 description 3
241000186362 Mycobacterium leprae Species 0.000 description 3
241000251539 Vertebrata <Metazoa> Species 0.000 description 3
230000001464 adherent effect Effects 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
210000002421 cell wall Anatomy 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
238000010586 diagram Methods 0.000 description 3
210000003722 extracellular fluid Anatomy 0.000 description 3
210000002744 extracellular matrix Anatomy 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
210000001365 lymphatic vessel Anatomy 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
230000001717 pathogenic effect Effects 0.000 description 3
210000003516 pericardium Anatomy 0.000 description 3
230000003248 secreting effect Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
210000001258 synovial membrane Anatomy 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
239000002699 waste material Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
101710098119 Chaperonin GroEL 2 Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
102000004388 Interleukin-4 Human genes 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
208000012659 Joint disease Diseases 0.000 description 2
206010062207 Mycobacterial infection Diseases 0.000 description 2
206010057249 Phagocytosis Diseases 0.000 description 2
241000700605 Viruses Species 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
230000001070 adhesive effect Effects 0.000 description 2
230000000240 adjuvant effect Effects 0.000 description 2
210000002588 alveolar type II cell Anatomy 0.000 description 2
230000005784 autoimmunity Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
230000007123 defense Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000001159 endocytotic effect Effects 0.000 description 2
239000012634 fragment Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000036571 hydration Effects 0.000 description 2
238000006703 hydration reaction Methods 0.000 description 2
229960001438 immunostimulant agent Drugs 0.000 description 2
239000003022 immunostimulating agent Substances 0.000 description 2
238000009169 immunotherapy Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229940028885 interleukin-4 Drugs 0.000 description 2
210000002664 langerhans' cell Anatomy 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
238000005461 lubrication Methods 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
230000001926 lymphatic effect Effects 0.000 description 2
210000003563 lymphoid tissue Anatomy 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
208000027531 mycobacterial infectious disease Diseases 0.000 description 2
239000003921 oil Substances 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
230000008782 phagocytosis Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
238000004064 recycling Methods 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
201000008827 tuberculosis Diseases 0.000 description 2
TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
101710145634 Antigen 1 Proteins 0.000 description 1
102000006410 Apoproteins Human genes 0.000 description 1
108010083590 Apoproteins Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
241000251729 Elasmobranchii Species 0.000 description 1
239000001263 FEMA 3042 Substances 0.000 description 1
208000005422 Foreign-Body reaction Diseases 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
102000043129 MHC class I family Human genes 0.000 description 1
108091054437 MHC class I family Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
102000040739 Secretory proteins Human genes 0.000 description 1
108091058545 Secretory proteins Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
230000000599 auto-anti-genic effect Effects 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
229940126587 biotherapeutics Drugs 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
238000002619 cancer immunotherapy Methods 0.000 description 1
238000009566 cancer vaccine Methods 0.000 description 1
229940022399 cancer vaccine Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000005859 cell recognition Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
230000008045 co-localization Effects 0.000 description 1
230000024203 complement activation Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000008260 defense mechanism Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000834 fixative Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
210000000497 foam cell Anatomy 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000008571 general function Effects 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
230000000762 glandular Effects 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
108091008147 housekeeping proteins Proteins 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
238000003365 immunocytochemistry Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
210000005007 innate immune system Anatomy 0.000 description 1
210000001911 interdigitating cell Anatomy 0.000 description 1
210000005133 interdigitating dendritic cell Anatomy 0.000 description 1
230000007154 intracellular accumulation Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
230000001788 irregular Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
KQAOIKIZSJJTII-UHFFFAOYSA-N p-mercuribenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C([Hg])C=C1 KQAOIKIZSJJTII-UHFFFAOYSA-N 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000011148 porous material Substances 0.000 description 1
210000004986 primary T-cell Anatomy 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
230000006432 protein unfolding Effects 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000003134 recirculating effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000004627 regenerated cellulose Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000002940 repellent Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
210000005212 secondary lymphoid organ Anatomy 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
241000894007 species Species 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000002344 surface layer Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
229920002258 tannic acid Polymers 0.000 description 1
LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
229940033123 tannic acid Drugs 0.000 description 1
235000015523 tannic acid Nutrition 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Dispersion Chemistry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20024571A 2000-03-24 2002-09-24 Fosfolipidblaere, modifiserte antigen-presenterende celler, fremgangsmate for inkorporering av antigener inn i dendrittiske celler og farmasoytisk sammensetning. NO333157B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0007150.6A GB0007150D0 (en)	2000-03-24	2000-03-24	Immunotherapeutic methods and compositions
PCT/GB2001/001936 WO2001072277A2 (en)	2000-03-24	2001-03-26	Immunotherapeutic methods and compositions

Publications (3)

Publication Number	Publication Date
NO20024571D0 NO20024571D0 (no)	2002-09-24
NO20024571L NO20024571L (no)	2002-10-14
NO333157B1 true NO333157B1 (no)	2013-03-18

Family

ID=9888324

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20024571A NO333157B1 (no)	2000-03-24	2002-09-24	Fosfolipidblaere, modifiserte antigen-presenterende celler, fremgangsmate for inkorporering av antigener inn i dendrittiske celler og farmasoytisk sammensetning.

Country Status (13)

Country	Link
US (2)	US20040110695A1 (da)
EP (1)	EP1267924B1 (da)
JP (1)	JP2004517031A (da)
AT (1)	ATE544470T1 (da)
AU (2)	AU5646101A (da)
CA (1)	CA2404325C (da)
DK (1)	DK1267924T3 (da)
ES (1)	ES2382070T3 (da)
GB (1)	GB0007150D0 (da)
NO (1)	NO333157B1 (da)
NZ (1)	NZ522058A (da)
PT (1)	PT1267924E (da)
WO (1)	WO2001072277A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0007150D0 (en) *	2000-03-24	2000-05-17	Lamellar Therapeutics Limited	Immunotherapeutic methods and compositions
GB0207653D0 (en) *	2002-04-03	2002-05-15	Lamellar Therapeutics Ltd	Methods of using lamellar bodies for therapeutic purposes
JP4545151B2 (ja) *	2003-02-06	2010-09-15	シーラスコーポレイション	非食細胞中への侵入について減弱化されているリステリア、そのリステリアを含むワクチン、およびそれらの使用法
US11324698B2 (en) *	2003-08-28	2022-05-10	Vgsk Technologies, Inc.	Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
GB0322448D0 (en) *	2003-09-25	2003-10-29	Lamellar Therapeutics Ltd	Using lamellar bodies to modify linear biological macro molecules
WO2005030226A1 (en) *	2003-09-25	2005-04-07	Lamellar Therapeutics Limited	Compositions and methods of using lamellar bodies for therapeutic purposes
ES2315880T3 (es) *	2004-07-07	2009-04-01	Statens Serum Institut	Composiciones y procedimientos para estabilizar formulaciones adyuvantes con base lipidica usando glucolipidos.
US20070299431A1 (en)	2006-05-02	2007-12-27	Green Medical, Inc.	Systems and methods for treating superficial venous malformations like spider veins
US7465312B2 (en)	2006-05-02	2008-12-16	Green Medical, Inc.	Systems and methods for treating superficial venous malformations like spider veins
JP5667180B2 (ja) *	2009-07-01	2015-02-12	イオンメディックスインコーポレイテッド	哺乳類の有核細胞に由来するマイクロベシクル及びその用途
AU2011271830B2 (en)	2010-07-01	2014-08-14	Aeon Medix Inc	Microvesicles derived from cell protoplast, and use thereof
EP3412282A1 (en) *	2011-06-02	2018-12-12	The Regents of the University of California	Membrane encapsulated nanoparticles and method of use
WO2015021390A2 (en)	2013-08-08	2015-02-12	The Regents Of The University Of California	Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
WO2015084677A1 (en)	2013-12-02	2015-06-11	Arytha Biosciences, Llc	Toxoid preparation and uses thereof
WO2015143295A2 (en)	2014-03-20	2015-09-24	The Regents Of The University Of California	Hydrogel compositions containing toxin-absorbing or binding nanoparticles and uses thereof
US11110127B2 (en)	2014-06-02	2021-09-07	Cellics Therapeutics, Inc.	Use of nanoparticles coated with red blood cell membranes to treat hemolytic diseases and disorders
US10434070B2 (en)	2015-01-02	2019-10-08	Cellics Therapeutics, Inc.	Use of nanoparticles coated with red blood cell membranes to enable blood transfusion
CN107530285B (zh)	2015-04-29	2021-07-27	加利福尼亚大学董事会	使用纳米粒子解毒
EP3632410A1 (en)	2018-10-05	2020-04-08	Lamellar Biomedical Limited	Lipidic polynucleotide carriers for cellular delivery
EP3692984A1 (en)	2019-02-08	2020-08-12	Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts	Annexin-coated particles

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5925375A (en) *	1987-05-22	1999-07-20	The Liposome Company, Inc.	Therapeutic use of multilamellar liposomal prostaglandin formulations
US5403592A (en) *	1987-08-25	1995-04-04	Macnaught Pty Limited	Lubricant composition for rheumatism
US5006343A (en) *	1988-12-29	1991-04-09	Benson Bradley J	Pulmonary administration of pharmaceutically active substances
FR2645878B1 (fr) *	1989-04-17	1994-02-25	Institut Nal Sante Recherc Medic	Sequences nucleotidiques d'actinomycetales, applications a la synthese ou a la detection d'acides nucleiques, produits d'expression de ces sequences et application en tant que compositions immunogenes
US5088499A (en) *	1989-12-22	1992-02-18	Unger Evan C	Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
WO1992021981A1 (en) *	1991-05-29	1992-12-10	Baxter International Inc.	Methods and compositions for the prevention, diagnosis, and treatment of inflammatory serosal disease and related conditions
JPH05339169A (ja) *	1992-03-03	1993-12-21	Dai Ichi Seiyaku Co Ltd	経口ワクチン
WO1997003703A1 (en) *	1995-07-21	1997-02-06	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
US5543152A (en) *	1994-06-20	1996-08-06	Inex Pharmaceuticals Corporation	Sphingosomes for enhanced drug delivery
US5462752A (en) *	1994-07-28	1995-10-31	Prp, Inc.	Inhibition of platelet binding
US5643599A (en) *	1995-06-07	1997-07-01	President And Fellows Of Harvard College	Intracellular delivery of macromolecules
CA2289742C (en) *	1997-05-08	2013-07-16	Biomira Inc.	Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
GB9807298D0 (en) *	1998-04-03	1998-06-03	Britannia Pharmaceuticals Ltd	Medicament
EP0976403A1 (en) *	1998-07-30	2000-02-02	Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO)	Adjuvant comprising pulmonary surfactant
US6193997B1 (en) *	1998-09-27	2001-02-27	Generex Pharmaceuticals Inc.	Proteinic drug delivery system using membrane mimetics
US6290987B1 (en) *	1998-09-27	2001-09-18	Generex Pharmaceuticals, Inc.	Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
GB0007150D0 (en) *	2000-03-24	2000-05-17	Lamellar Therapeutics Limited	Immunotherapeutic methods and compositions
GB0207653D0 (en) *	2002-04-03	2002-05-15	Lamellar Therapeutics Ltd	Methods of using lamellar bodies for therapeutic purposes
GB0322448D0 (en) *	2003-09-25	2003-10-29	Lamellar Therapeutics Ltd	Using lamellar bodies to modify linear biological macro molecules

2000
- 2000-03-24 GB GBGB0007150.6A patent/GB0007150D0/en not_active Ceased
2001
- 2001-03-26 AT AT01929778T patent/ATE544470T1/de active
- 2001-03-26 PT PT01929778T patent/PT1267924E/pt unknown
- 2001-03-26 US US10/239,576 patent/US20040110695A1/en not_active Abandoned
- 2001-03-26 AU AU5646101A patent/AU5646101A/xx active Pending
- 2001-03-26 WO PCT/GB2001/001936 patent/WO2001072277A2/en active IP Right Grant
- 2001-03-26 CA CA2404325A patent/CA2404325C/en not_active Expired - Lifetime
- 2001-03-26 EP EP01929778A patent/EP1267924B1/en not_active Expired - Lifetime
- 2001-03-26 JP JP2001570238A patent/JP2004517031A/ja active Pending
- 2001-03-26 AU AU2001256461A patent/AU2001256461B2/en not_active Ceased
- 2001-03-26 ES ES01929778T patent/ES2382070T3/es not_active Expired - Lifetime
- 2001-03-26 DK DK01929778.7T patent/DK1267924T3/da active
- 2001-03-26 NZ NZ522058A patent/NZ522058A/en not_active IP Right Cessation
2002
- 2002-09-24 NO NO20024571A patent/NO333157B1/no not_active IP Right Cessation
2006
- 2006-07-24 US US11/491,177 patent/US20080069866A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PT1267924E (pt)	2012-05-24
US20040110695A1 (en)	2004-06-10
CA2404325C (en)	2012-06-12
GB0007150D0 (en)	2000-05-17
US20080069866A1 (en)	2008-03-20
ES2382070T3 (es)	2012-06-05
JP2004517031A (ja)	2004-06-10
ATE544470T1 (de)	2012-02-15
NO20024571L (no)	2002-10-14
NO20024571D0 (no)	2002-09-24
EP1267924B1 (en)	2012-02-08
AU5646101A (en)	2001-10-08
WO2001072277A2 (en)	2001-10-04
NZ522058A (en)	2005-05-27
EP1267924A2 (en)	2003-01-02
AU2001256461B2 (en)	2005-06-30
CA2404325A1 (en)	2001-10-04
WO2001072277A3 (en)	2002-06-13
DK1267924T3 (da)	2012-05-29

Legal Events

Date	Code	Title	Description
2019-10-28	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO333157B1 (no)	2013-03-18	Fosfolipidblaere, modifiserte antigen-presenterende celler, fremgangsmate for inkorporering av antigener inn i dendrittiske celler og farmasoytisk sammensetning.
JP4164361B2 (ja)	2008-10-15	増強した免疫応答を有するワクチン、およびその調製方法
ES2239457T3 (es)	2005-09-16	Procedimiento para regular a niveles mas bajos la actividad de ligando de osteoprotegerina.
AU2001256461A1 (en)	2001-12-20	Immunotherapeutic methods and compositions
JP7506930B2 (ja)	2024-06-27	クラミジア種（Ｃｈｌａｍｙｄｉａｓｐ．）に対するワクチン
CN101180312A (zh)	2008-05-14	来自尿路病原性大肠杆菌的免疫原
JP2007308508A (ja)	2007-11-29	クラミジアワクチン
BR112020016373A2 (pt)	2020-12-15	Composição imunogênica compreendendo antígenos de estafilococos
Jiang et al.	2015	Hepatitis B virus core antigen as a carrier for Chlamydia trachomatis MOMP multi-epitope peptide enhances protection against genital chlamydial infection
JP4935761B2 (ja)	2012-05-23	家禽大腸菌症ワクチン
NO335784B1 (no)	2015-02-16	Liposomvaksine omfattende antigenisk materiale fra finne-fisk patogener.
US6733762B1 (en)	2004-05-11	Method of using Zot to inhibit lymphocyte proliferation in an antigen-specific manner
TW201815414A (zh)	2018-05-01	用於免疫作用中有效抗體生産的新穎蛋白質結構
JPH09505039A (ja)	1997-05-20	ワクチンの設計および製造
KR100615442B1 (ko)	2006-08-25	항원-특이적 방식으로 림프구 증식을 저해하기 위한 조트또는 조눌린의 사용방법
Nain et al.	1987	Elicitation of protective immunity to Entamoeba histolytica—an experimental study
JP2001527562A (ja)	2001-12-25	リポ多糖コアに対するワクチン
JP2022544407A (ja)	2022-10-18	免疫原性組成物
Parmar	1999	Development and characterization of a liposomal subunit vaccine against Neisseria Gonorrhoeae
CN117979992A (zh)	2024-05-03	钩端螺旋体毒力调节蛋白及其用途
AU2001266197A1 (en)	2002-01-14	Contraceptive vaccines for pest control